stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Return on assets
Krystal Biotech, Inc.'s return on assets over the twelve months to 30 September 2026 was 15.9%, down 1.2 percentage points from fiscal 2025 (17.1%). Over the past ten years it has ranged from −30.3% (fiscal 2017) to 17.1% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 17.1% | 7.63 |
| FY2024 | 9.51% | 7.92 |
| FY2023 | 1.59% | 25.22 |
| FY2022 | −23.6% | (8.78) |
| FY2021 | −14.9% | (2.47) |
| FY2020 | −12.4% | (0.64) |
| FY2019 | −11.7% | 1.36 |
| FY2018 | −13.1% | 17.19 |
| FY2017 | −30.3% | (25.89) |
| FY2016 | −4.40% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| KRYS Krystal Biotech, Inc. | 15.9% |
| PTGX Protagonist Therapeutics, Inc. compare | 10.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.1% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| SYRE Spyre Therapeutics, Inc. compare | −30.9% |
| CYTK Cytokinetics, Incorporated compare | −47.7% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement